Table 1. Clinical and profiling data.

		Tissue/Blood exome sequencing			Plasma DNA exome sequencing					dPCR breakpoint profiling
SampleID	Clincal data	Tumor*	Blood*	Nbr point mutations	cfDNA source	DNA (ng)	Plasma*	Fraction ctDNA	P-value	DNA (ng)	Fraction ctDNA
SWE-54_B	Gleason 5+4, T3A	87	86	27**	Before surgery	3	39	0.001	0.265	NA	NA
SWE-54_A	Gleason 5+4, T3A	87	86	27**	1 month after surgery	8	42	0	1	NA	NA
BC_A	Elston 3, prolif 75%, 21 mm, ER+, PR+, HER2+	122	147	26	Before surgery	5	62	0	1	5	NA
BC_B	Elston 3, prolif 70%, 18 mm, ER+, HER2+	114	137	184	Before surgery	1	18	0	1	1	0
BC_C	Elston 2, prolif 13%, 16 mm, ER+, PR+	111	146	17	Before surgery	5	57	0	1	5	0
BC_D	Elston 3, prolif 90%, 18 mm, ER+, HER2+	101	118	245	Before surgery	3	43	0.003	1.16E-18	3	0.026
BC_E	Elston 1, prolif 10%, 38 mm, ER+, PR+	134	188	20	Before surgery	5	55	0	1	5	NA
BC_F	Elston 2, prolif 2%, 12 mm, ER+, PR+	175	153	82	Before surgery	5	48	0	1	5	0
BC_G	Elston 3, prolif 85%, 24 mm, ER+, PR+	163	168	47	Before surgery	5	39	0	1	5	0

*Mean coverage throughout the exome.

**The point mutations originate from the two lymph-node metastases that were sequenced in ref 15.